| Literature DB >> 20407806 |
Hiroyuki Tsuda1, Takahiro Kozu, Gen Iinuma, Yasuo Ohashi, Yutaka Saito, Daizo Saito, Takayuki Akasu, David B Alexander, Mitsuru Futakuchi, Katsumi Fukamachi, Jiegou Xu, Tadao Kakizoe, Masaaki Iigo.
Abstract
Colorectal cancer (CRC) is one of the most frequently diagnosed cancers and, despite improved colonoscopic screening, CRC is a leading cause of death from cancer. Administration of bovine lactoferrin (bLF) suppresses carcinogenesis in the colon and other organs of test animals, and recently it was shown that ingestion of bLF inhibits the growth of adenomatous polyps in human patients. Here we review work which established bLF as an anti-carcinogenic agent in laboratory animals and the results of a clinical trial which demonstrated that bLF can reduce the risk of colon carcinogenesis in humans.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20407806 DOI： 10.1007/s10534-010-9331-3
Source DB: PubMed Journal: Biometals ISSN： 0966-0844 Impact factor: 2.949